Biotech | April 08, 2026
Stipple Bio raises $100M Series A to advance next-gen cancer therapies
The new capital is expected to fund the company through 2029
The new capital is expected to fund the company through 2029
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Harbour BioMed brings advanced antibody discovery platforms to the table
Subscribe To Our Newsletter & Stay Updated
